ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Часто задаваемые вопросы
В каком секторе работает ARCA biopharma, Inc (ABIO)?
ARCA biopharma, Inc относится к сектору Здравоохранение.
Выплачивает ли ARCA biopharma, Inc (ABIO) дивиденды?
Нет, ARCA biopharma, Inc не выплачивает дивиденды.